Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-02-15
DOI
10.1111/bjh.15801
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
- (2018) Ann S. LaCasce et al. BLOOD
- Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial
- (2018) Andrea Gallamini et al. JOURNAL OF CLINICAL ONCOLOGY
- Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
- (2018) Jie Zhou et al. SEMINARS IN IMMUNOLOGY
- Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy
- (2018) Jan Walewski et al. BRITISH JOURNAL OF HAEMATOLOGY
- Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1–2 trial
- (2018) Peter D Cole et al. LANCET ONCOLOGY
- Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma
- (2017) Cinzia Pellegrini et al. Oncotarget
- Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models
- (2016) F. Li et al. CANCER RESEARCH
- CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro
- (2016) Hinrich P. Hansen et al. Oncotarget
- The prognostic value of the myeloid-mediated immunosuppression marker Arginase-1 in classic Hodgkin lymphoma
- (2016) Alessandra Romano et al. Oncotarget
- Non-steady-state hematopoiesis regulated by the C/EBPβ transcription factor
- (2015) Hideyo Hirai et al. CANCER SCIENCE
- Myeloid Cell-Derived Reactive Oxygen Species Externally Regulate the Proliferation of Myeloid Progenitors in Emergency Granulopoiesis
- (2015) Hyun-Jeong Kwak et al. IMMUNITY
- PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
- (2015) Alison J Moskowitz et al. LANCET ONCOLOGY
- Brentuximab Vedotin in Transplant-Naive Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients
- (2015) P. L. Zinzani et al. ONCOLOGIST
- Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner
- (2015) Rikke B. Holmgaard et al. Cell Reports
- CURRENT ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
- (2015) Luca Castagna et al. Mediterranean Journal of Hematology and Infectious Diseases
- Circulating myeloid-derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up-front with a risk-adapted strategy
- (2014) Alessandra Romano et al. BRITISH JOURNAL OF HAEMATOLOGY
- Recurrent Hodgkin lymphoma: toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents
- (2014) Antonello Pinto et al. LEUKEMIA & LYMPHOMA
- IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
- (2014) Francesco Di Raimondo et al. Mediterranean Journal of Hematology and Infectious Diseases
- Immune suppression by neutrophils and granulocytic myeloid-derived suppressor cells: similarities and differences
- (2013) Janesh Pillay et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- CD30 Expression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndromes
- (2013) Wenli Zheng et al. Clinical Lymphoma Myeloma & Leukemia
- International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers
- (2013) A. Biggi et al. JOURNAL OF NUCLEAR MEDICINE
- Advances in the Treatment of Relapsed or Refractory Hodgkin's Lymphoma
- (2012) R. Ramchandren ONCOLOGIST
- Where Does Brentuximab Vedotin Fit into the Management of Patients with Hodgkin Lymphoma?
- (2012) Sagun D. Goyal et al. Current Hematologic Malignancy Reports
- Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
- (2011) C. H. Moskowitz et al. BLOOD
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now